Prostate cancer screens could improve with gene technology, as firms seek to find an alternative...


Prostate cancer screens could improve with gene technology, as firms seek to find an alternative to the industry standard PSA blood test. Two companies set to capitalize on the $740M market for a better test are Myriad Genetics (MYGN +1.3%) and Genomic Health (GHDX +0.3%), says InvestorPlace.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs